Arcellx, Inc.
ACLXDelisted Apr 28, 2026- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001786205
Arcellx, Inc. was delisted on Apr 28, 2026; its insiders filed their last Form 4 on Apr 28, 2026; 240 institutions reported holding it in 13F filings for Q1 2026, worth $6.52B in total; Soros Fund Management was the only superinvestor holding it.
Q2 2022 vs. Q1 2022
How the institutions holding Arcellx, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 49 | 1 | 68 | +20 |
| Shares | 26.9M | 2.23K | 34.9M | +8.06M (+30.0%) |
| Value | $357.9M | $31.0K | $621.5M | +$263.7M (+73.7%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (23)
Institutions that held Arcellx, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
Sold out (3)
Institutions that held Arcellx, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Goldman Sachs Group Inc | 58,059 | $814.0K |
| Squarepoint Ops LLC | 30,000 | $421.0K |
| Centiva Capital, LP | 11,348 | $159.0K |
Not filed for Q2 2022 yet (1)
Institutions that held Arcellx, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 2,229 | $31.0K |